Back to Search
Start Over
Hepcidin agonists as therapeutic tools.
- Source :
-
Blood [Blood] 2018 Apr 19; Vol. 131 (16), pp. 1790-1794. Date of Electronic Publication: 2018 Mar 09. - Publication Year :
- 2018
-
Abstract
- Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.<br /> (© 2018 by The American Society of Hematology.)
- Subjects :
- Animals
Hemochromatosis metabolism
Hemochromatosis pathology
Hepcidins metabolism
Humans
Iron metabolism
Polycythemia Vera metabolism
Polycythemia Vera pathology
beta-Thalassemia metabolism
beta-Thalassemia pathology
Hemochromatosis drug therapy
Hepcidins agonists
Polycythemia Vera drug therapy
beta-Thalassemia drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 131
- Issue :
- 16
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 29523504
- Full Text :
- https://doi.org/10.1182/blood-2017-11-737411